Fig. 1 · Structure

Documents & Downloads

Tegobuvir (GS-9190)

Cat. No. A11583 CAS 1000787-75-6

NS5B polymerase inhibitor

Tegobuvir (GS-9190 is a non-nucleoside NS5B polymerase inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
Huh-7 EC50 0.005 μM Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells after 48 hrs by luciferase reporter gene assay [PMID: 24224729]

Tegobuvir (GS-9190) Research Summary

This section summarizes 1 in vitro study of Tegobuvir (GS-9190) from 1 published reference. In vitro models include GT 1b replicon in the the HeLa cell line.

Tegobuvir (GS-9190) In Vitro Studies

Tegobuvir was evaluated against a replicon in HeLa cells following addition to cell plates, with untreated cells as the control. Tegobuvir was reported to be vastly less potent against this replicon. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Tegobuvir antiviral activity in a HeLa cell replicon model

Cell-based study · GT 1b (Con-1) replicon in the the HeLa cell line [1]

Tegobuvir was added to plates containing a HeLa cell replicon model and was reported to be vastly less potent against this replicon.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
antiviral effectEC50 EC50>10 µM[1]

Literature-Reported Treatment Conditions

Exposure duration
72 hours
Method
subsequent addition to cell plates
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: Tegobuvir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Replicon EC50 determinations (S20, S21, S22, S23); Results > NS5B doublet formation correlates with TGV potency (S91)

antiviral effect: antiviral effect; comparator: untreated cells — Methods > Replicon EC50 determinations (S23); Results > NS5B doublet formation correlates with TGV potency (S91)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1000787-75-6
Applications NS5B polymerase inhibitor
Formula C25H14F7N5
Molecular Weight 517.41
Synonyms GS9190; GS 333126
SMILES
C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 89 mg/mL (172.01 mM)
Water Insoluble
Ethanol 89 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tegobuvir (GS-9190) Research References

  1. [1] Hebner CM, Han B, Brendza KM, et al. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One (2012). PMID: 22720059 DOI: 10.1371/journal.pone.0039163 Source material

Added to your cart

View Cart Checkout
Loading...